GTSM:3176

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Medigen Biotechnology Corp. focuses on the development of therapies for liver diseases and cancers in Taiwan. More Details

Rewards

Earnings have grown 8.6% per year over the past 5 years

Risk Analysis

No risks detected for 3176 from our risk checks.


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Medigen Biotechnology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 3176 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 3176's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

-6.4%

3176

-0.005%

TW Biotechs

2.5%

TW Market


1 Year Return

-15.5%

3176

22.8%

TW Biotechs

31.6%

TW Market

Return vs Industry: 3176 underperformed the TW Biotechs industry which returned 22.8% over the past year.

Return vs Market: 3176 underperformed the TW Market which returned 31.6% over the past year.


Shareholder returns

3176IndustryMarket
7 Day-6.4%-0.005%2.5%
30 Day-15.3%-7.0%11.8%
90 Day-17.4%-2.4%22.9%
1 Year-15.5%-15.5%23.3%22.8%36.3%31.6%
3 Year35.1%35.1%-18.4%-19.9%59.7%41.8%
5 Year-28.6%-28.6%-50.0%-50.4%136.2%94.8%

Long-Term Price Volatility Vs. Market

How volatile is Medigen Biotechnology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Medigen Biotechnology undervalued compared to its fair value and its price relative to the market?

4.83x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 3176's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 3176's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 3176 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.

PE vs Market: 3176 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 3176's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 3176's PB Ratio (4.8x) is in line with the TW Biotechs industry average.


Next Steps

Future Growth

How is Medigen Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

86.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medigen Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Medigen Biotechnology performed over the past 5 years?

8.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 3176 is currently unprofitable.

Growing Profit Margin: 3176 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 3176 is unprofitable, but has reduced losses over the past 5 years at a rate of 8.6% per year.

Accelerating Growth: Unable to compare 3176's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 3176 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.4%).


Return on Equity

High ROE: 3176 has a negative Return on Equity (-37.05%), as it is currently unprofitable.


Next Steps

Financial Health

How is Medigen Biotechnology's financial position?


Financial Position Analysis

Short Term Liabilities: 3176's short term assets (NT$1.5B) exceed its short term liabilities (NT$976.6M).

Long Term Liabilities: 3176's short term assets (NT$1.5B) exceed its long term liabilities (NT$1.2B).


Debt to Equity History and Analysis

Debt Level: 3176's debt to equity ratio (50.5%) is considered high.

Reducing Debt: 3176's debt to equity ratio has increased from 26.9% to 50.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 3176 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 3176 has sufficient cash runway for 1 years if free cash flow continues to grow at historical rates of 7% each year.


Next Steps

Dividend

What is Medigen Biotechnology current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 3176's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 3176's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 3176's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 3176's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 3176's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Stanley Chang (61 yo)

no data

Tenure

Dr. Shi-Chung Chang, also known as Stanley, MD, Ph.D., serves as the Chairman and Chief Executive Officer of Medigen Biotechnology Corporation. Dr. Chang is a Urological surgeon by training, and was former...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Medigen Biotechnology Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Medigen Biotechnology Corp.
  • Ticker: 3176
  • Exchange: GTSM
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NT$6.949b
  • Shares outstanding: 138.99m
  • Website: https://www.medigen.com.tw

Location

  • Medigen Biotechnology Corp.
  • No.3, Park Street
  • 14th Floor
  • Taipei City
  • 11503
  • Taiwan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
3176GTSM (Taipei Exchange)YesCommon StockTWTWDDec 2003

Biography

Medigen Biotechnology Corp. focuses on the development of therapies for liver diseases and cancers in Taiwan. The company offers PI-88 (MUPAFOSTAT) that is in Phase III clinical trial for the treatment of ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/23 08:49
End of Day Share Price2021/01/22 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.